Aflibercept and ranibizumab — Competitive Intelligence Brief

Aflibercept and ranibizumab (Aflibercept and ranibizumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-VEGF agent. Area: Ophthalmology.

marketed Anti-VEGF agent VEGF-A (and VEGF-B for aflibercept) Ophthalmology Small molecule

Target snapshot

Aflibercept and ranibizumab (Aflibercept and ranibizumab) — Instituto de Olhos de Goiania. Aflibercept and ranibizumab are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aflibercept and ranibizumab TARGET	Aflibercept and ranibizumab	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (and VEGF-B for aflibercept)
Ranibizumab and Aflibercept	Ranibizumab and Aflibercept	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (vascular endothelial growth factor-A)
Primary Medical Treatment Pathway	Primary Medical Treatment Pathway	Moorfields Eye Hospital NHS Foundation Trust	marketed	anti-VEGF agent	VEGF
intravitreal ranibizumab & photodynamic therapy	intravitreal ranibizumab & photodynamic therapy	University Hospital, Basel, Switzerland	phase 3	Anti-VEGF agent	VEGF-A
Sham to ranibizumab	Sham to ranibizumab	Novartis	phase 3	anti-VEGF agent	VEGF-A
ranibizumab intravitreal injection	ranibizumab intravitreal injection	Hawaii Pacific Health	phase 3	anti-VEGF agent	VEGF-A
Ranibizumab + deferred laser	Ranibizumab + deferred laser	Jaeb Center for Health Research	phase 3	anti-VEGF agent	VEGF-A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-VEGF agent class)

1. Instituto de Olhos de Goiania · 2 drugs in this class
2. University Hospital, Basel, Switzerland · 1 drug in this class